🟢 Kyverna Therapeutics is trading 13% up in pre-market after durable one-year miv-cel responses

Kyverna Therapeutics is trading 13% higher at $8.00 after reporting positive one-year miv-cel data in stiff person syndrome and longer-term generalized myasthenia gravis results.

• Results showed durable clinical responses and favorable safety, with no high-grade CRS, ICANS or IEC-HS through one year.
• Kyverna plans to add the data to its rolling FDA submission in the fourth quarter.
• The broader biotech sector is stronger pre-market, but the company-specific clinical update is the clearest catalyst.